Voclosporin - Generic Drug Details

What are the generic drug sources for voclosporin and what is the scope of freedom to operate?

Voclosporin is the generic ingredient in one branded drug marketed by Aurinia and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Voclosporin has two hundred patent family members in forty countries.

There is one drug master file entry for voclosporin. One supplier is listed for this compound.

Summary for voclosporin

International Patents:	200
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	22
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for voclosporin
What excipients (inactive ingredients) are in voclosporin?	voclosporin excipients list
DailyMed Link:	voclosporin at DailyMed

Recent Clinical Trials for voclosporin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Chinese PLA General Hospital	EARLY_PHASE1
NephroNet, Inc.	PHASE4
Aurinia Pharmaceuticals Inc.	PHASE3

See all voclosporin clinical trials

Pharmacology for voclosporin

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors P-Glycoprotein Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for voclosporin

L04AD	Calcineurin inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for VOCLOSPORIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUPKYNIS	Capsules	voclosporin	7.9 mg	213716	8	2025-01-22

US Patents and Regulatory Information for voclosporin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes	10,286,036
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes	7,332,472		Y	Y
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes	11,622,991
Aurinia	LUPKYNIS	voclosporin	CAPSULE;ORAL	213716-001	Jan 22, 2021		RX	Yes	Yes

EU/EMA Drug Approvals for voclosporin

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Lupkynis	voclosporin	EMEA/H/C/005256Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).	Authorised	no	no	no	2022-09-15

International Patents for voclosporin

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1435910	NOUVEAUX PRECONCENTRES EN MICROEMULSION D'ANALOGUES DE CYCLOSPORINE (NOVEL CYCLOSPORIN ANALOG MICROEMULSION PRECONCENTRATES)
Japan	2006328543	ELECTROPOLISHING AND/OR ELECTROPLATING APPARATUS AND METHOD
Russian Federation	2004110941
Brazil	0213659
Argentina	036852	PRECONCENTRADO DE UNA MICROEMULSION DE ANALOGOS DE CICLOSPORINA, SU METODO DE PREPARACION Y METODOS PARA PRODUCIR INMUNOSUPRESION

Voclosporin (Lupkynis): Market Dynamics and Financial Trajectory

Last updated: April 26, 2026

Voclosporin is marketed as Lupkynis for active lupus nephritis. After a rapid initial ramp, demand has been constrained by a narrower-than-peak addressable population and by competitive pressure in lupus nephritis. Financial performance has tracked those forces through product-specific sales growth, payer and guideline adoption cycles, and competitive substitution among immunosuppressive and steroid-sparing regimens.

What is the market “shape” for voclosporin in lupus nephritis?

Therapy positioning

Voclosporin is used in adult patients with active lupus nephritis as part of a background regimen (typically including corticosteroids and mycophenolate). Its value proposition is built around:

• Earlier disease control relative to historical baselines in some trial designs
• Lower corticosteroid exposure in steroid-sparing approaches
• Oral administration as part of combination therapy

Adoption constraints that shape demand

Demand is sensitive to four practical dynamics:

1. Patient selection and line-of-therapy

   • Lupus nephritis management remains heterogeneous across nephrology practices and geographies.
   • Use is typically concentrated in patients who match labeled populations and in centers comfortable with calcineurin inhibitor monitoring.

2. Safety monitoring and clinical workflow

   • Calcineurin inhibitor class constraints (lab monitoring, drug interaction vigilance) can slow uptake compared with therapies perceived as easier to manage.

3. Payer coverage and formulary inclusion

   • Coverage decisions in immunology and nephrology often hinge on evidence strength in the payer’s target subpopulation and on economic comparisons versus alternatives.

4. Guideline and consensus cycles

   • Uptake tends to lag trial publication through guideline updates, clinician comfort, and retrospective evidence in routine care.

Competitive landscape

The competitive set is dominated by:

• Other immunosuppressants and steroid-sparing regimens used in lupus nephritis
• Brands and biosimilars that can displace portions of the treated population through pricing and preferred formulary status
• Biologic and targeted immunology approaches that compete on efficacy, safety profiles, and steroid minimization narratives

The practical effect for voclosporin is a market that grows, then plateaus unless incremental adoption is unlocked via guideline inclusion, expanded clinical comfort, and improved contracting.

How has voclosporin sales performed and what does the trend imply?

Revenue trajectory and key inflection points

Voclosporin’s financial trajectory has followed a common rare-and-specialty-drug pattern:

• Launch and early ramp driven by clinical enthusiasm for steroid-sparing lupus nephritis approaches
• Subsequent normalization as uptake met real-world bottlenecks: patient identification, payer coverage, and competition
• Later plateau/slowdown if incremental patient penetration did not keep pace with increasing market skepticism and substitution

What to watch in the financial trajectory

In lupus nephritis, the market is narrow enough that a small shift in:

• Net price
• Payer mix
• Formulary placement
• Prescriber adoption can materially change revenue outcomes.

Financial indicators that map to those levers:

• U.S. and ex-U.S. segment mix (ex-U.S. growth often depends on reimbursement pathways)
• Gross-to-net pressure (rebates, contracting)
• Share-of-treated-patient dynamics versus competing regimens

What market dynamics drive quarter-to-quarter volatility for voclosporin?

Contracting and reimbursement

Quarterly performance for specialty drugs often reflects:

• Contracting cycles and regional payer negotiations
• Changes in rebate structures tied to formulary status
• Shifts in channel inventory dynamics

For voclosporin, which is administered chronically during active disease management windows, inventory effects can be visible but are typically secondary to:

• New patient starts
• Treatment persistence within labeled regimens

Demand generation versus clinician inertia

Voclosporin demand is particularly sensitive to clinician behavior:

• Nephrologists and rheumatologists have different prescribing habits and thresholds for calcineurin inhibitor use.
• Education and clinical familiarity drive conversion from “trial adoption” to routine practice.

Safety profile and switching behavior

Safety monitoring requirements can lower willingness-to-switch for some patients, and can slow persistence if monitoring logistics become a burden. That can limit:

• Rapid expansion into broader subgroups
• Uptake in systems with limited lab monitoring capacity

Where does voclosporin fit economically versus alternatives?

Value proposition that supports pricing

Voclosporin’s economic case generally rests on:

• Improved renal outcomes within lupus nephritis populations treated early in disease course
• Reduced steroid exposure translating into lower steroid-related toxicity and downstream costs (where payers value avoided complications)

Where the pricing case weakens

Pricing pressure rises when:

• Clinicians perceive non-voclosporin regimens as close enough on outcomes
• Payers negotiate harder as market maturity reduces “launch premium”
• Competitors achieve preferred status through contracts and uptake momentum

How do lifecycle forces affect voclosporin’s financial outlook?

Real-world adoption ceiling

The key structural question for voclosporin is how quickly it can expand treated prevalence relative to:

• Diagnosed active lupus nephritis incidence
• Eligibility under labeling and clinical consensus
• Switching and persistence patterns

If treated eligibility remains steady but competitive substitution increases, revenues plateau even as market expands slowly.

Competition and sequencing

The lupus nephritis treatment sequence influences long-term revenue:

• If voclosporin remains an early-line option, persistence can support revenue.
• If it shifts toward later lines due to payer policies or clinical preference, uptake can slow.

Regulatory and label expansion effects

Any incremental label expansion can change:

• Addressable population size
• Clinician willingness to adopt
• Payer confidence in coverage

In absence of label expansion momentum, sales often track the slope of continued guideline uptake and contracting execution rather than rapid growth.

What are the business implications for investors and R&D partners?

The core market bet

The fundamental investment question is whether voclosporin can:

• Increase net starts (new patient initiation)
• Preserve net price (avoid escalating gross-to-net erosion)
• Maintain persistence (avoid switching to other regimens once on therapy)

A stable patient-start base with modest net price erosion typically produces flat revenue growth. Faster revenue growth requires acceleration in patient starts or expansion in average selling price via payer contracting improvements.

How to interpret financial trajectory signals

For voclosporin, monitor:

• Whether sales growth is driven by volume (starts and persistence) versus contracting
• Whether new formularies open in categories that previously excluded calcineurin inhibitor-based approaches
• Whether competitive positioning leads to share loss in the early treatment window

Key Takeaways

• Voclosporin’s market dynamics reflect a narrow, label-driven lupus nephritis population with adoption constrained by patient selection, monitoring logistics, and contracting.
• The financial trajectory has followed a launch ramp into normalization as payer mix, formulary status, and competitive substitution reduced incremental growth.
• Quarter-to-quarter outcomes are most sensitive to net contracting effects and new patient initiation rather than manufacturing or broad market demand.
• Sustained growth depends on expanding treated starts and protecting net price while maintaining persistence within combination lupus nephritis regimens.

FAQs

1) What drives demand for voclosporin in lupus nephritis?

Demand is driven by clinician adoption for labeled lupus nephritis populations, payer coverage, and the ability of health systems to support calcineurin inhibitor monitoring within combination regimens.

2) Why does voclosporin sales growth often slow after launch?

Adoption ceilings emerge from patient eligibility constraints, safety monitoring workflow, and competitive substitution once payer contracting matures beyond launch-era preferences.

3) What are the biggest financial risks for voclosporin?

Gross-to-net pressure from contracting, share loss to alternative lupus nephritis regimens, and any persistence decline due to monitoring burden or switching behavior.

4) How should investors assess whether growth is volume-led or price-led?

Track whether revenue gains align with net start growth and persistence indicators versus changes in average net selling price and gross-to-net impacts.

5) What would improve voclosporin’s long-term market penetration?

Broader guideline acceptance for routine use, improved payer formulary access, and evidence or real-world data that strengthens confidence in efficacy and steroid-minimization benefits.

References

[1] Food and Drug Administration. Lupkynis (voclosporin) prescribing information.
[2] U.S. Securities and Exchange Commission. Company filings for voclosporin’s manufacturer (Lupkynis product owner), including quarterly and annual reports.
[3] Company investor materials (earnings releases and investor presentations). Lupkynis sales updates and pipeline/strategy commentary.
[4] Clinical guidance and consensus documents on lupus nephritis management (updates used by payers and prescribers).